Minimizing the Maximum Expected Sample Size in Two-Stage Phase II Clinical Trials with Continuous Outcomes
Open Access
- 31 May 2012
- journal article
- research article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 22 (4) , 836-852
Abstract
Two-stage designs are commonly used for Phase II trials. Optimal two-stage designs have the lowest expected sample size for a specific treatment effect, for example, the null value, but can perform poorly if the true treatment effect differs. Here we introduce a design for continuous treatment responses that minimizes the maximum expected sample size across all possible treatment effects. The proposed design performs well for a wider range of treatment effects and so is useful for Phase II trials. We compare the design to a previously used optimal design and show it has superior expected sample size properties.Keywords
This publication has 13 references indexed in Scilit:
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A simple two‐stage design for quantitative responses with application to a study in diabetic neuropathic painPharmaceutical Statistics, 2008
- Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2007
- An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapiesContemporary Clinical Trials, 2007
- Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future DirectionsJournal of Clinical Oncology, 2005
- Admissible two‐stage designs for phase II cancer clinical trialsStatistics in Medicine, 2004
- A sample size adjustment procedure for clinical trials based on conditional powerBiostatistics, 2002
- Optimal two-stage designs for single arm Phase II cancer trialsJournal of Biopharmaceutical Statistics, 2002
- Optimal two-sided group sequential testsSequential Analysis, 1995
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989